ALLK - Allakos Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.55
-0.95 (-1.09%)
At close: 4:00PM EDT

86.55 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close87.50
Open87.07
Bid86.32 x 800
Ask86.63 x 900
Day's Range85.76 - 89.99
52 Week Range29.34 - 92.84
Volume337,520
Avg. Volume676,435
Market Cap4.19B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.61
Earnings DateAug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est100.67
Trade prices are not sourced from all markets
  • Will Allakos Continue to Surge Higher?
    Zacks

    Will Allakos Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Allakos.

  • Top Ranked Momentum Stocks to Buy for August 9th
    Zacks

    Top Ranked Momentum Stocks to Buy for August 9th

    Top Ranked Momentum Stocks to Buy for August 9th

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 7, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Walt Disney Co (NYSE: DIS ) shares were down ...

  • GlobeNewswire

    Allakos Announces Upsizing and Pricing of Public Offering of Common Stock

    Allakos Inc. (the “Company”) (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the upsizing and pricing of its previously announced underwritten public offering. The size of the offering has been increased from the previously announced $200 million of shares of the Company’s common stock to $350 million of shares of its common stock. The Company is offering 4,545,454 shares at a public offering price of $77.00 per share.

  • GlobeNewswire

    Allakos Announces Proposed Public Offering of Common Stock

    Allakos Inc. (the “Company”) (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $200 million of shares of its common stock in an underwritten public offering. In addition, Allakos expects to grant the underwriters a 30-day option to purchase up to $30 million of additional shares of the Company’s common stock.  All of the shares in the proposed offering will be sold by the Company. Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering.

  • Why Is Allakos Soaring Today?
    Market Realist

    Why Is Allakos Soaring Today?

    Today, Allakos (ALLK) announced favorable results from its Phase 2 trial evaluating investigational therapy AK002.

  • Schaeffer's Investment Research

    Pharma Stock Set to Double Today

    The stock is at the top of the Nasdaq today

  • Small Biotech Doubles as Drug Shows Promise in Rare Diseases
    Bloomberg

    Small Biotech Doubles as Drug Shows Promise in Rare Diseases

    (Bloomberg) -- Shares of Allakos Inc. more than doubled after a mid-stage study of its medicine in a pair of rare diseases showed significant improvements for patients.The U.S. drugmaker surged the most on record as analysts touted the results, bringing its market capitalization to $2.8 billion from $1.3 billion at the close of trading on Friday. William Blair’s Tim Lugo said the company is taking “a leadership position in the eosinophilic gastrointestinal disease market.” The study assessed the medicine in 59 patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, rare diseases that impact the stomach and gastrointestinal tract.Bearish bets against the Palo Alto, California-based company remain elevated compared to peers, with short interest at 28% of float, according to financial analytics firm S3 Partners, down from its year highs of 31% in January.Wall Street may be on the lookout for the company to take advantage of the record session with the company reporting cash and equivalents of $153.1 million in earnings this morning. Allakos hasn’t offered shares since a July public offering last year. A potential offering could be in the range of $250 million and $300 million given the stock’s market value.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • GlobeNewswire

    Allakos Reports Second Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Aug. 05, 2019 -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell.

  • TheStreet.com

    Allakos Stock Doubles on Positive Stomach Disease Drug Study Data

    Analyst at William Blair says Allakos is a leader in research for a treatment for a rare stomach disease.

  • Imagine Owning Allakos (NASDAQ:ALLK) And Wondering If The 17% Share Price Slide Is Justified
    Simply Wall St.

    Imagine Owning Allakos (NASDAQ:ALLK) And Wondering If The 17% Share Price Slide Is Justified

    Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

  • Ohio Capital Fund's management firm seeks 3-year extension, raise
    American City Business Journals

    Ohio Capital Fund's management firm seeks 3-year extension, raise

    The firm managing the state-backed bond fund attracting venture capital investment to Ohio is asking for three more years to wrap up the program.

  • GlobeNewswire

    Allakos Reports First Quarter 2019 Financial Results

    REDWOOD CITY, Calif., May 08, 2019 -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases,.

  • GlobeNewswire

    Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis

    -- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic.

  • Is Allakos Inc. (ALLK) A Good Stock To Buy?
    Insider Monkey

    Is Allakos Inc. (ALLK) A Good Stock To Buy?

    Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]

  • GlobeNewswire

    Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights

    REDWOOD CITY, Calif., March 14, 2019 -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases,.

  • State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why
    American City Business Journals

    State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why

    Ohio Capital Fund LLC used $7 million in state tax credits to meet the fund of fund's February payments on its bonds, as portfolio companies show signs of success.

  • GlobeNewswire

    Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis

    REDWOOD CITY, Calif., Feb. 19, 2019 -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases,.

  • Allakos Enters Oversold Territory
    Zacks

    Allakos Enters Oversold Territory

    Allakos Inc. (ALLK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire

    Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

    -- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by.

  • GlobeNewswire

    Allakos to Host Investor Day on February 19 in New York City

    Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19th starting at 12:00 pm ET in New York City. The event will feature an overview of the AK002 development program, including a presentation of the chronic urticaria and indolent systemic mastocytosis (ISM) clinical results to date by Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité University in Berlin, a noted expert in the field of urticaria, indolent systemic mastocytosis, and other allergic conditions.

  • GlobeNewswire

    Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

    Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results from two additional chronic urticaria cohorts: patients with cholinergic urticaria and symptomatic dermographism (also referred to as dermatographic urticaria). Earlier this month, Allakos reported that 12 of 13 patients (92%) in the Xolair-naïve chronic spontaneous urticaria (CSU) cohort achieved a complete response with AK002. Top-line results for the remaining urticaria cohort, patients with chronic spontaneous urticaria who failed to respond to Xolair, are expected later in the first quarter of 2019.

  • GlobeNewswire

    Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients

    Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive top-line results for the Xolair-naïve chronic spontaneous urticaria (CSU) cohort from its Phase 2 study. The principle investigator is Dr. Marcus Maurer, MD, Professor of Dermatology and Allergy at Charité University in Berlin. The Xolair-naïve chronic spontaneous urticaria cohort enrolled 13 patients with uncontrolled urticaria despite treatment with H1 antihistamines at doses of up to 4 times the labeled dosage.

  • American City Business Journals

    Here are the winners and losers from Bay Area's IPO class of 2018

    Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.